Head-to-head · WeighScore
AbundRX vs OrderlyMeds
The verdict
OrderlyMeds takes it — 72.4/100 to 66.6/100.
OrderlyMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OrderlyMeds is a telehealth provider selling compounded semaglutide and tirzepatide with no membership fees or hidden costs.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AbundRX | OrderlyMeds |
|---|---|---|
| WeighScore | 66.6/100 | 72.4/100 |
| Grade | C | C |
| Scorecard rank | #181 | #78 |
| Semaglutide | $179/mo (compounded) | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) |
| Tirzepatide | $279/mo (compounded) | $299/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #181 · C
Strengths
- Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
- Fast, free shipping and a simple few-minute online health assessment
- Provider-guided care connecting patients with licensed US clinicians
- Publishes Terms, Privacy, and Refund policies
Where it loses points
- Claims LegitScript certification in text but displays no verifiable seal or listing
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Compounding pharmacy not named; no HIPAA notice found; state availability not published
- Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Graded #78 · C
Strengths
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
- Brand-name routes are priced openly, at retail
Where it loses points
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
- Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.